Last updated: May 22, 2026
Executive summary: Iopromide is an approved iodinated contrast medium used in CT, angiography, and urologic imaging. Because iopromide’s core market is a mature, low-differentiation small-molecule contrast class, incremental value is driven mainly by (1) volume growth in imaging utilization, (2) product quality and supply reliability, (3) format expansion (concentration, volume, ready-to-use vs single-dose), and (4) regulatory and payer dynamics around utilization management. A reliable, litigation-grade clinical-trials and exclusivity-based projection requires a specific iopromide product/strength and a target jurisdiction set; without that, any attempt to time launches, gauge remaining patent/market exclusivity, or project revenue by year would be incomplete.
Is iopromide in active clinical trials, and what are the latest study themes?
Short answer: Iopromide trials tend to be utilization, imaging performance, safety in specific subpopulations, and protocol comparisons within radiology workflows rather than first-in-class “new entity” development. Meaningful updates require trial registries linked to particular brand formulations and routes (e.g., IV vs intra-arterial, CT vs angiography), and to endpoints (contrast-induced nephropathy, allergy/hypersensitivity, image quality metrics).
What indications are most likely to appear in iopromide trial pipelines?
In iopromide, the most common “trial-shaped” questions in radiology typically include:
- Contrast-associated safety: hypersensitivity reactions, mild-to-moderate allergic history, and renal impairment populations (contrast-induced acute kidney injury risk stratification).
- Imaging performance: arterial/venous phase adequacy, opacification, diagnostic accuracy, noise/artifact measures.
- Dose/concentration optimization: lower volume or alternative concentration strategies while maintaining image quality.
- Workflow comparisons: premedication protocols, injection rate protocols, or product handling formats (single-dose vs bulk).
Which iopromide routes shape clinical-trials reporting?
- IV for CT (most volume-relevant)
- Intra-arterial for angiography
- Urologic imaging (retrograde studies, depending on local labeling)
How big is the global iopromide market, and what growth drivers matter most?
Short answer: The iopromide market tracks global diagnostic imaging utilization (especially CT) and the iodinated contrast medium competitive category. Growth is mostly volume and treatment mix, not new clinical breakthroughs.
Key demand drivers
- CT utilization growth: increasing adoption in oncology staging, emergency care, and outpatient imaging.
- Aging demographics: higher baseline imaging needs.
- Hospital throughput and turnaround time: pushes demand for reliable ready-to-use formats.
- Renal-safety protocols: may shift utilization patterns among contrast options, but iopromide is already embedded in many formularies.
Offsetting headwinds
- Formulary pressure: pricing pressure across contrast classes, especially where payers use therapeutic interchangeability.
- Supply chain risk: iodinated contrast manufacturing is capacity- and raw-material-sensitive.
- Regulatory changes: label restrictions or safety communications can alter switching behavior within the class.
Which companies dominate iopromide supply, and how does the competitive landscape affect price?
Short answer: The iodinated contrast market is typically shared between originators and multiple generics. For iopromide specifically, competitive pressure usually reflects (1) generic penetration in specific strengths and formats, (2) distribution coverage, and (3) tender wins in hospital systems.
Competitive implications for market projection
- Tender-driven pricing: hospital and group purchasing organization contracts can reset local price floors.
- Switching friction: radiology departments often stick with established injection protocols and supply agreements, slowing rapid brand-to-generic switching unless forced by procurement.
- Portfolio depth: suppliers with broader SKU coverage (concentrations/volumes) win share when procurement consolidates.
When will iopromide patents or exclusivity expire, and how does this affect generic entry risk?
Short answer: iopromide is an older small molecule used widely in multiple jurisdictions. For credible “when does exclusivity end” analysis, the key unit is not “iopromide,” but the specific marketed product (brand/generic, strength, and route) and its listed patents in that jurisdiction. Without an anchored product label, any exclusivity timeline would be speculative.
What to check for exclusivity and patent barriers
- Regulatory reference: which branded reference product the iopromide SKU relies on (if any) in the relevant market.
- Patent scope: method-of-use claims for specific imaging protocols or renal-safety regimens, if any; formulation/device claims are often limited for classic contrast solutions.
- Orphan/other special exclusivity: typically not relevant for established contrast actives.
What is the Orange Book status of iopromide products, and where do Paragraph IV challenges matter?
Short answer: “Orange Book status” is product-specific. Iopromide’s active ingredient is not enough to determine listings, listed patents, or whether any generic applicant filed Paragraph IV certifications. A defensible Orange Book view requires the specific FDA-listed NDA/ANDA entries for iopromide strengths and dosage forms.
How Paragraph IV would translate into market timing
- If iopromide products have listed patents with enforceable claims, Paragraph IV can trigger:
- automatic 30-month stay,
- litigation-based launch timing shifts,
- or settlement-based earlier/later entry.
- Without product-linked listings, market-timing conclusions cannot be made without risking factual error.
What clinical safety signals matter most for iopromide uptake, and how do they change utilization?
Short answer: Uptake is dominated by hypersensitivity and renal impairment risk management. In practice, utilization changes through:
- guideline-driven selection,
- premedication protocols,
- and institutional contrast nephropathy pathways.
Renal impairment and contrast-associated kidney injury
Clinical adoption is shaped by how hospitals apply:
- screening for baseline eGFR thresholds,
- hydration protocols,
- contrast volume minimization,
- and comparative choice among iodinated agents.
Hypersensitivity management
Even when reactions are rare, the availability of standardized premedication pathways affects adoption decisions and tender selection.
How does iopromide compare with other iodinated contrast media in performance and formulary position?
Short answer: In most formularies, iopromide competes within a portfolio of nonionic, low-osmolar iodinated contrast media. Comparative advantage is often practical rather than molecular:
- viscosity and injection comfort,
- image quality under typical CT protocols,
- renal-safety pathway fit,
- and total acquisition cost.
What “comparison endpoints” drive purchasing decisions?
- incidence of adverse events under local patient mix,
- image adequacy and diagnostic yield,
- injection feasibility (rate, pressure, patient tolerance),
- and supply reliability for high-throughput radiology sites.
What delivery formats and strengths drive differentiation in iopromide revenue?
Short answer: Market share within iodinated contrast is SKU-level. Revenue projection is sensitive to:
- concentration (e.g., higher vs lower iodine density choices),
- injection volume packs,
- single-use vs multi-dose handling,
- and labeling expansion for specific imaging settings.
What does an iopromide market forecast look like for 2026–2031?
Short answer: A credible forecast must be grounded in:
- the specific iopromide product(s) and jurisdictions,
- the competitive generic share at SKU/strength level,
- and the timing of tender renewals and any regulatory actions affecting switching.
Without those anchored inputs, any numerical forecast would be non-actionable.
Framework for projection (usable for investment and licensing models)
- Unit demand: grow with CT utilization and procedure volume.
- Share shift: generic penetration within specific SKUs.
- Price: driven by tender cycles and substitution rates.
- Compliance: risk communications can cause temporary switching.
- Capacity/supply: shortages can create short-term share volatility.
Key Takeaways
- Iopromide’s growth is primarily tied to imaging utilization and SKU-level procurement rather than novel clinical differentiation.
- Market and exclusivity analysis must be product- and jurisdiction-specific; “iopromide” alone is insufficient for patent/exclusivity timelines, Orange Book status, or Paragraph IV timing.
- Safety and protocol alignment (renal risk management, hypersensitivity pathway) shape utilization and formularies more than molecule-level attributes at this stage.
- A forecast for 2026–2031 should be built from CT procedure volume trends, tender-driven pricing, and SKU-level generic share evolution.
FAQs
- How do renal impairment guidelines change iodinated contrast agent selection, including iopromide?
- Which iopromide strengths and injection formats typically experience the fastest generic substitution in tenders?
- What clinical endpoints are used to compare iodinated contrast media for CT image quality and diagnostic yield?
- How do product-specific FDA listings and patent schedules determine generic launch timing for iodinated contrast media?
- What supply chain or manufacturing capacity factors most often disrupt iodinated contrast availability and shift purchasing?
References
(None provided; no sources cited in the response.)
